Name: 6ix Investment Platform
Brand: 6ix

Latest Press Releases

Time	Headline
14m ago	Samsung Biologics Reports First Quarter 2026 Financial Results
40m ago	EQT AB (publ) Q1 Announcement 2026
40m ago	2026 ASCO Preview \| Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
41m ago	Q1 2026 Production Report
41m ago	Broadridge Launches Central Risk and Liquidity Optimization Solution to Unify Trade Execution, Liquidity and Risk Management

Samsung Biologics Co Ltd (KO:207940) — investor relations, events, news, and company updates on 6ix.

Latest News

Community Chat